TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00579280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quetiapine SR
Description: flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: divalproex sodium ER
Description: Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
Study: NCT04447391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise program
Description: Combined exercise programme, consisting of warm-up, aerobic exercise, resistance training, and cool-down, 3 days a week after school for 50 minutes from 17;30 under supervision by a trainer plus 300 kcal deficit diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 300 kcal deficit diet only
Study: NCT00579280

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT02482480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Dietary and general recommendations
Study: NCT03625375

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention consist of aerobic, stretchig, pelvic motions, kegels and relaxation exercises
Study: NCT01160081

Intervention type: OTHER
Intervention: Serum sample
Description: Serum samples collected
Study: NCT01160848

Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with saline water and occluded with Tegaderm

Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with saline water

Intervention type: DRUG
Group type: OTHER
Intervention: Area cleaned with Ethyl alcohol solution

Intervention type: DRUG
Group type: OTHER
Intervention: Visonac left on the skin for 24 hours in facial area one

Intervention type: DRUG
Group type: OTHER
Intervention: Visonac wiped off after one hour

Intervention type: DRUG
Group type: OTHER
Intervention: Visonac left on the skin 24 hours in facial area two
Study: NCT02379182

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard clinical care
Description: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard clinical care
Description: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard clinical care
Description: adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation at sensory level
Description: The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical stimulation at motor level
Description: The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
Study: NCT03848403

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered SC
Study: NCT00956566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: dietary counseling, group teaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dietary intervention
Description: dietary counseling, group teaching
Study: NCT00637208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venographic occlusion of spermatic veins
Description: Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
Study: NCT00031486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Description: Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
Study: NCT03685591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06952229
Description: Oral 7 days on / 7 days off - 28 day cycles (Part 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Prostate Cancer (Part 2). 160mg, capsules, orally, daily
Study: NCT02070484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NuCel

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Bone Matrix
Study: NCT00101933

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic DBS Therapy for epilepsy
Description: Stimulation On

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Medtronic DBS Therapy for epilepsy
Description: Stimulation Off
Study: NCT00694005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: kissing balloon
Description: simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without kissing balloon angioplasty leave alone
Description: simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
Study: NCT01414621

Intervention type: OTHER
Intervention: atrial tissue sample
Description: atrial tissue sample from CABG patient
Study: NCT03984370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207
Description: Abdominal SC administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207
Description: Abdominal SC administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline)
Description: Abdominal SC administration
Study: NCT00582309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucommander-Guided Intravenous Insulin Infusion
Description: Glucommander-Guided Intravenous Insulin Infusion.~* Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~* During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intravenous Insulin Infusion
Description: Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.~Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving \>80 units/day of insulin as an outpatient.~Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simple Calculated Intravenous Insulin Infusion
Description: If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
Study: NCT01931280

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Counseling
Description: Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
Study: NCT00353587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 200 mg once daily for 16 weeks
Study: NCT00468741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS (Comprehensive Health Enhancement Support System)
Description: Full CHESS for subject use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: informational services of CHESS available to subject

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHESS
Description: CHESS informational services and social support available to subject
Study: NCT00981305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactate-containing vaginal lubricant
Description: vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal lubricant
Description: vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
Study: NCT04713696

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional training
Description: Functional training refers to exercises that targets the muscles of the lumbopelvic-hip complex in order for them to more appropriately support and control the spine.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine training
Description: Routine training refers to general exercises that perform before and after practice, including jogging, stretching and strengthening exercises for upper and lower extremities
Study: NCT03503357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing1
Description: Command List A

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 2
Description: Command List B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 3
Description: Command List C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IFT Testing 4
Description: Command List D
Study: NCT03121001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: 0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine
Description: 30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
Study: NCT00353587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 400 mg once daily for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-102
Description: MBX-102 600 mg once daily for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MBX-102 Placebo once daily for 16 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: Actos 30 mg once daily for 16 weeks
Study: NCT02283281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: 1:1 THC to CBD standardized extract from cannabis plant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: 1:1 THC to CBD standardized extract from cannabis plant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy oromucosal
Description: drops containing only Olive oil vehicle without the active compound (i.e.: without Cannabis oil)
Study: NCT03547843

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based education
Description: The group-based educational program consists of two sessions that run over two consecutive weeks. Each session consists of a lecture from a recruited expert on the topic of the session and by expert patients with a following discussion of the topic facilitated by the course leader.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waiting list
Description: No educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Diagnostic treatment with medication. In addition, some patients receive cognitive behavioral therapy (not systematically given to every patient). If needed, patients are also offered assistance with regard to economy, housing, education, and work as well as contact with family and network.
Study: NCT02472210

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Description: An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin
Description: An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
Study: NCT02827006

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corrective osteotomy distal radius
Description: Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: corrective osteotomy distal radius
Description: Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
Study: NCT04510675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test Article
Description: Omeza Collagen Matrix

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Control
Description: Occlusive Patch of 0.9% sodium chloride, NaCl
Study: NCT04430751

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical QiGong training
Description: The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medical QiGong training
Description: The study intervention consisted of a 12-week training program that introduced students to a progressive series of 10 QiGong forms that are designed to build upon each other to restore balance and function and to enhance well-being. These forms involve both physical movement and visualization.
Study: NCT03440684

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: At the beginning of the training, participants were informed about the anatomy and biomechanics of core muscles and the effectiveness core stabilization exercises.~In all sessions, 5 minutes warm-up exercises and 5 minutes cool-down exercises were done before training. The exercises were first shown by the physiotherapist 2 to 3 repetitions and then the participants performed the exercise 10 to 12 repetitions.~Participants were included clinical pilates exercises for 6 weeks, which would be 3 days per week. Exercise programme were managed by one and the same physiotherapist. Each week the level of difficulty of the exercises was increased according to the tolerance of the participants and new exercises were added to the program.
Study: NCT01952184

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CBSvit HS device
Description: closed vitrification with closed storage

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryotop SC device
Description: open vitrification with closed storage
Study: NCT02736695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 AV 1451
Description: Tau binding agent
Study: NCT00173108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinic-based intervention program and home-based intervention program
Description: The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: clinic-based intervention program and home-based intervention program
Description: The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
Study: NCT01674374

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules
Description: Given PO
Study: NCT01185444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hya-Joint
Description: The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyalgan
Description: The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.